Merck's experimental skin disease drug succeeds in mid-stage study | Reuters

Merck's experimental skin disease drug succeeds in mid-stage study

Merck reported positive mid-stage trial results for an experimental drug targeting a painful skin disease, marking progress in the company's dermatology pipeline.